Drugs / Plozasiran
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed familial chylomicronemia syndrome 2 milestones | |||||
| Filed | China (NMPA) | — | familial chylomicronemia syndrome | 2025-01-26 | “submitted a New Drug Application (NDA) for plozasiran to the National Medical Products Administration (NMPA) in China for the treatment of FCS” arrowheadpharma.com ↗ “Plozasiran, has had its new drug application (NDA) (Acceptance No. JXHS2500018) officially accepted” visirna.com ↗ |
| Filed | US (FDA) | — | familial chylomicronemia syndrome | 2024-11-18 | “submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS)” arrowheadpharma.com ↗ “Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome” arrowheadpharma.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Approved | EU (EMA) | Redemplo | — | 2026-06-19 | europa.eu ↗ |
| Approved | US (FDA) | REDEMPLO | — | 2025-11-18 | fda.gov ↗ |
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05413135 | Jul 2022 → Sep 2025 | hyperlipidemia | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04720534 | May 2021 → Mar 2023 | — | Arrowhead Pharmaceuticals | Completed | Met primary |
| Phase 37 trials · 4 met primary | ||||||
| Phase 3 | NCT06880770 | Apr 2025 → Mar 2029 expected | — | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06822790 | Apr 2025 → Jul 2028 expected | hypertriglyceridemia | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06347016 | Jul 2024 → Jun 2026 overdue | — | Arrowhead Pharmaceuticals | Active not recruiting | Met primary |
| Phase 3 | NCT06347003 | Jul 2024 → Jun 2026 overdue | — | Arrowhead Pharmaceuticals | Active not recruiting | Met primary |
| Phase 3 | NCT06347133 | May 2024 → Jun 2026 overdue | hypertriglyceridemia | Arrowhead Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05902598 | Jul 2023 → Nov 2024 | familial chylomicronemia syndrome | Visirna Therapeutics HK Limited | Completed | Met primary |
| Phase 3 | NCT05089084 | Dec 2021 → Apr 2024 | familial chylomicronemia syndrome | Arrowhead Pharmaceuticals | Completed | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT06796426 | — | familial chylomicronemia syndrome, hypertriglyceridemia | Arrowhead Pharmaceuticals | Available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05757596 Comparator | May → Sep 2023 | — | Visirna Therapeutics HK Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 41
| Date | Issuer | Release |
|---|---|---|
| 2026-08-30 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) |
| 2026-08-17 | Arrowhead Pharmaceuticals | Regulatory People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides arrowheadpharma.com ↗
Following its marketing authorization by the European Commission in June 2026, REDEMPLO® (plozasiran) is now listed in the Lauer-Taxe® database and thus able to be prescribed, dispensed and reimbursed in Germany. |
| 2026-08-04 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). |
| 2026-07-22 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is associated with repeated hospital admissions and can be fatal. |
| 2026-06-22 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). |
| 2026-05-26 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress arrowheadpharma.com ↗
New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment |
| 2026-05-01 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. |
| 2026-04-24 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). |
| 2026-03-28 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG). |
| 2026-01-15 | Sanofi | Regulatory Press Release: Myqorzo and Redemplo approved in China sanofi.com ↗
Myqorzo and Redemplo approved in China |
| 2026-01-07 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). |
| 2026-01-05 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. |
| 2025-12-02 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (SHTG) (TG levels greater than or equal to 500 mg/dL). |
| 2025-11-18 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). |
| 2025-03-17 | Visirna Therapeutics HK Limited | Results Visirna Announce Positive Topline Results from Phase 3 Clinical Trial of Plozasiran (VSA001) in Chinese Patients in China with Familial Chylomicronemia Syndrome visirna.com ↗
Visirna Therapeutics (Suzhou) Co., Ltd. today announced positive topline results from the Phase 3 clinical trial conducted by Visirna (CTR20231418/NCT05902598) of investigational plozasiran in Chinese patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. |
| 2025-01-26 | Visirna Therapeutics HK Limited | Regulatory Visirna Announces NMPA Acceptance of New Drug Application for Plozasiran visirna.com ↗ |
| 2025-01-17 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. |
| 2025-01-07 | Visirna Therapeutics HK Limited | Regulatory Plozasiran (VSA001) Granted Priority Review in China for patients with Familial Chylomicronemia Syndrome (FCS) visirna.com ↗
Visirna announced that the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) of China granted priority review for Plozasiran (VSA001) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS). |
| 2024-11-18 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. |
| 2024-11-18 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. |
| 2024-09-10 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease characterized by extremely high triglyceride levels which can cause acute and potentially fatal pancreatitis. |
| 2024-09-02 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. |
| 2024-08-19 | Visirna Therapeutics HK Limited | Regulatory Visirna's APOC3 Targeted siRNA - VSA001 Receives IND Approval for Phase III International MRCT in China visirna.com ↗
Visirna Therapeutics (Shanghai) Co., Ltd. ("Visirna") announced that the National Medical Products Administration has approved the Investigational New Drug (IND) application for an international Multi-Regional Clinical Trial (MRCT) of Visirna’s VSA001 injection, an APOC3 targeted siRNA therapeutic. |
| 2024-06-03 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. |
| 2024-05-28 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia. |
| 2024-04-07 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). |
| 2023-11-13 | Arrowhead Pharmaceuticals | Results Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 arrowheadpharma.com ↗
Plozasiran achieved mean max reductions of up to 90% in APOC3 and 87% in triglycerides in patients with severe hypertriglyceridemia |
| 2023-09-18 | Visirna Therapeutics HK Limited | Regulatory Visirna Announces Breakthrough Therapy Designation Granted for VSA001 for Treatment of Adults with Familial Chylomicronemia Syndrome in China visirna.com ↗
Visirna today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation (BTD) for VSA001 for the treatment of adults with familial chylomicronemia syndrome (FCS) in China. |
| 2023-03-20 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 arrowheadpharma.com ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). |
| 2022-11-07 | Arrowhead Pharmaceuticals | Results Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline arrowheadpharma.com ↗
ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia |
| 2021-11-15 | Arrowhead Pharmaceuticals | Results Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021 arrowheadpharma.com ↗
APOC3 was reduced by 98% in FCS patients and 96% in MCM patients |
| 2021-11-01 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences arrowheadpharma.com ↗
Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia |
| 2021-03-01 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia arrowheadpharma.com ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with hypertriglyceridemia. |
| 2020-11-13 | Arrowhead Pharmaceuticals | Results Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020 arrowheadpharma.com ↗
ARO-APOC3 achieved triglyceride reductions of 74-92% |
| 2020-08-31 | Arrowhead Pharmaceuticals | Results Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 arrowheadpharma.com ↗
These positive results from the healthy volunteer, repeat-dose portion of the Phase 1/2 clinical studies of our cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, strongly support our plans to rapidly advance both drug candidates into later stage development. |
| 2020-02-05 | Arrowhead Pharmaceuticals | Results Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 arrowheadpharma.com ↗
The interim results from the multiple-dose portion of the Phase 1 studies of Arrowhead’s cardiometabolic candidates ARO-APOC3 and ARO-ANG3 are highly encouraging and support our belief that RNAi may be the optimal mechanism to inhibit APOC3 and ANGPTL3. |
| 2019-11-18 | Arrowhead Pharmaceuticals | Results Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019 arrowheadpharma.com ↗
The data were presented in two late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2019, in Philadelphia. |
| 2019-09-16 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3 arrowheadpharma.com ↗
These initial clinical data also indicate that ARO-APOC3 and ARO-ANG3 administration led to a long duration of effect that potentially enables once every three-month or once every six-month dosing intervals. |
| 2019-06-21 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3 arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-APOC3 for the treatment of familial chylomicronemia syndrome (FCS). |
| 2019-01-07 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia arrowheadpharma.com ↗ |
| 2018-05-11 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline arrowheadpharma.com ↗
The new preclinical data presented on ARO-APOC3 and ARO-ANG3 included the following:: |
All press releases naming this drug 57 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plozasiran | “Plozasiran (VSA001, ARO-APOC3) is an RNA interference therapy that targets Apolipoprotein C3 (APOC3), a key regulator of lipoprotein metabolism.” PMID 41094680 ↗ Oct 202510“Plozasiran, a hepatocyte-targeted siRNA against apolipoprotein C-III” PMID 42291067 ↗ Mar 2026 “Plozasiran induced significant dose-dependent” PMID 38583092 ↗ Jul 2024 |
| Known as | ADS-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068438 ↗ |
| Known as | ADS-005 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068438 ↗ |
| Known as | ARO-APOC3 | “Plozasiran (VSA001, ARO-APOC3) is an RNA interference therapy that targets Apolipoprotein C3 (APOC3), a key regulator of lipoprotein metabolism.” PMID 41094680 ↗ Oct 2025 |
| Known as | VSA001 | “Plozasiran (VSA001, ARO-APOC3) is an RNA interference therapy that targets Apolipoprotein C3 (APOC3), a key regulator of lipoprotein metabolism.” PMID 41094680 ↗ Oct 2025 |
| Action | Inhibit | “reduces hepatic production of apolipoprotein C-III” PMID 39225259 ↗ Sep 2024 |
| Modality | Small interfering RNA (siRNA) | “Plozasiran is a small interfering RNA” PMID 39225259 ↗ Sep 2024 |
| Route | Subcutaneous | “receive subcutaneous plozasiran (25- or 50-mg)” PMID 41923352 ↗ Apr 2026 |
| Target | APOC3 | “Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III” PMID 39225259 ↗ Sep 2024 |